{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Readmission rate is defined as the frequency at which patients are readmitted (after initial post-transplant discharge) following post-infusion of mobilized PBSC product for reasons other than progressive disease/relapse","groups":[{"description":"XM02 Filgrastim (Granix) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)\n\nPlerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)\n\nApheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)","id":"OG000","title":"XM02 Filgrastim (Granix) and Plerixafor"},{"description":"Filgrastim (Neupogen) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)\n\nPlerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)\n\nApheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)","id":"OG001","title":"Filgrastim (Neupogen) and Plerixafor"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"(2) participants in the XM02 Filgrastim (Granix) \\& Plerixafor arm did not receive ASCT and were not evaluable for this outcome measure. (1) participant in the Filgrastim (Neupogen) \\& Plerixafor arm did not receive ASCT and were not evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to Day 100","title":"Comparison of the Readmission Rate Between the Two Arms","type":"SECONDARY","unitOfMeasure":"Participants"}